Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Mitoxantrone (formerly known as NSC-301739; CL232325; Mitozantrone; Novantrone; Mitroxone; Neotalem; Onkotrone; Pralifan), the hydrochloride salt of Mitoxantrone which is an approved anticancer medication, is a potent type II topoisomerase inhibitor with potential antitumor activity. In HepG2 and MCF-7/wt cells, it inhibits TOPO II with IC50s of 2.0 μM and 0.42 mM, respectively. It is a proven treatment for multiple sclerosis and an anti-neoplastic for leukemia and other cancers. Through its suppression of DNA synthesis and cell cycle progression, mitoxantrone treated leukemia. It affected various immune cells, including macrophages, T cells, and B cells. The interference caused multiple DNA strand breaks (DSBs), chromatin structure changes, and other effects. It was related to TOPO-II-mediated DNA cleavage.
Targets |
PKC ( IC50 = 8.5 μM ); Topoisomerase II
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C22H28N4O6
|
---|---|
Molecular Weight |
444.48
|
Exact Mass |
444.2
|
Elemental Analysis |
C, 59.45; H, 6.35; N, 12.61; O, 21.60
|
CAS # |
65271-80-9
|
Related CAS # |
70476-82-3;70711-41-0
|
Appearance |
Solid powder
|
SMILES |
C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
|
InChi Key |
KKZJGLLVHKMTCM-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
|
Chemical Name |
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
|
Synonyms |
NSC-301739; DHAQ; CL-232325; NSC301739; CL 232325; NSC 301739; CL232325; Mitozantrone; Mitoxantrone HCl; Mitoxantrone dihydrchloride; US brand name: Novantrone. Foreign brand names: Mitroxone; Neotalem; Onkotrone; Pralifan.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: Saline: 30 mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2498 mL | 11.2491 mL | 22.4982 mL | |
5 mM | 0.4500 mL | 2.2498 mL | 4.4996 mL | |
10 mM | 0.2250 mL | 1.1249 mL | 2.2498 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04797767 | Recruiting | Drug: Mitoxantrone Drug: Venetoclax |
Myeloid Neoplasm Acute Myeloid Leukemia |
University of Washington | February 4, 2022 | Phase 1 |
NCT02553460 | Active Recruiting |
Drug: Mitoxantrone Drug: ITMHA |
Acute Lymphoblastic Leukemia | St. Jude Children's Research Hospital |
January 29, 2016 | Phase 1 Phase 2 |
NCT03026842 | Active Recruiting |
Drug: Mitoxantrone, Cytarabine Drug: Decitabine |
Acute Myeloid Leukemia | The First Hospital of Jilin University |
January 2017 | Phase 4 |
NCT03441048 | Active Recruiting |
Drug: Mitoxantrone Drug: G-CSF |
Acute Myeloid Leukemia | Medical College of Wisconsin | May 22, 2018 | Phase 1 |
NCT04330820 | Active Recruiting |
Drug: Venetoclax Oral Tablet | Relapsed Adult AML Refractory AML |
Technische Universität Dresden | April 6, 2020 | Phase 1 Phase 2 |